58 related articles for article (PubMed ID: 28976021)
1. Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: Results from a 5-year cohort study.
Facciorusso A; Del Prete V; Turco A; Buccino RV; Nacchiero MC; Muscatiello N
J Gastroenterol Hepatol; 2018 Apr; 33(4):942-949. PubMed ID: 28976021
[TBL] [Abstract][Full Text] [Related]
2. Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus.
Chekuri S; Nickerson J; Bichoupan K; Sefcik R; Doobay K; Chang S; DelBello D; Harty A; Dieterich DT; Perumalswami PV; Branch AD
PLoS One; 2016; 11(7):e0159413. PubMed ID: 27442255
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive assessment of liver stiffness in right heart failure: A new phenotype requiring further exploration.
Patterson MT; Prins KW
J Heart Lung Transplant; 2024 Jul; 43(7):1116-1117. PubMed ID: 38518864
[No Abstract] [Full Text] [Related]
4. Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness: A systematic review and meta-analysis.
Erman A; Sathya A; Nam A; Bielecki JM; Feld JJ; Thein HH; Wong WWL; Grootendorst P; Krahn MD
J Viral Hepat; 2018 May; 25(5):502-513. PubMed ID: 29239068
[TBL] [Abstract][Full Text] [Related]
5. Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
de Lédinghen V; Laforest C; Hézode C; Pol S; Renault A; Alric L; Larrey D; Métivier S; Tran A; Jézéquel C; Samuel D; Zoulim F; Tual C; Pailhé A; Gibowski S; Bourlière M; Bellissant E; Pawlotsky JM
Clin Infect Dis; 2018 Mar; 66(7):1013-1018. PubMed ID: 29077864
[TBL] [Abstract][Full Text] [Related]
6. Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection.
Chen Yi Mei SLG; Thompson AJ; Christensen B; Cunningham G; McDonald L; Bell S; Iser D; Nguyen T; Desmond PV
PLoS One; 2017; 12(10):e0185609. PubMed ID: 29065124
[TBL] [Abstract][Full Text] [Related]
7. Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement.
Tag-Adeen M; Sabra AM; Akazawa Y; Ohnita K; Nakao K
Hepat Med; 2017; 9():45-53. PubMed ID: 29062242
[TBL] [Abstract][Full Text] [Related]
8. Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
Korda D; Lenard ZM; Gerlei Z; Jakab Z; Haboub-Sandil A; Wagner L; Varga M; Cseprekal O; Marton A; Horvathy D; Takacs S; Doros A; Mathe Z
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):27-32. PubMed ID: 29049126
[TBL] [Abstract][Full Text] [Related]
9. New Therapies for Treating Hepatitis C Virus: Impact on Laboratory Testing Recommendations and Clinical Management.
Tolan NV; Horowitz GL; Graham CS; Hillyard D; Osburn W; Ray S
Clin Chem; 2017 Dec; 63(12):1799-1805. PubMed ID: 29018029
[No Abstract] [Full Text] [Related]
10. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
[TBL] [Abstract][Full Text] [Related]
11. Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India.
Garg G; Dixit VK; Shukla SK; Singh SK; Sachan S; Tiwari A; Yadav VK; Yadav DP
J Clin Exp Hepatol; 2018 Sep; 8(3):241-249. PubMed ID: 30302040
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of OP-724 in patients with haemophilia and liver cirrhosis due to HIV/HCV coinfection: an investigator-initiated, open-label, non-randomised, single-centre, phase I study.
Kimura K; Tanuma J; Kimura M; Imamura J; Yanase M; Ieiri I; Kurosaki M; Watanabe T; Endo T; Yotsuyanagi H; Gatanaga H
BMJ Open Gastroenterol; 2024 Apr; 11(1):. PubMed ID: 38677720
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication.
Vutien P; Kim NJ; Moon AM; Johnson KM; Berry K; Green PK; Ioannou GN
Aliment Pharmacol Ther; 2024 Feb; 59(3):361-371. PubMed ID: 37955206
[TBL] [Abstract][Full Text] [Related]
14. Implementing Better Standard Instruments for Detecting Cirrhosis in Hepatitis C Patients.
Fagala MD; Shpak Y
Cureus; 2023 Sep; 15(9):e44597. PubMed ID: 37795065
[TBL] [Abstract][Full Text] [Related]
15. The Prevalence of Liver Fibrosis Stages on More than 23,000 Liver Stiffness Measurements by Vibration-Controlled Transient Elastography: A Single Center Study.
Lazar A; Sporea I; Lungeanu D; Mare R; Lupusoru R; Popescu A; Danila M; Deleanu A; Dan I; Lascau A; Popa A; Sirli R
Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685341
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Long-Term Outcomes of Direct Acting Antiviral Agents in Chronic Kidney Disease Subjects: A Single Center Cohort Study.
Czarnecka P; Czarnecka K; Tronina O; Bączkowska T; Wyczałkowska-Tomasik A; Durlik M; Czerwinska K
J Clin Med; 2023 May; 12(10):. PubMed ID: 37240622
[TBL] [Abstract][Full Text] [Related]
17. Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents.
Cossiga V; La Civita E; Bruzzese D; Guarino M; Fiorentino A; Sorrentino R; Pontillo G; Vallefuoco L; Brusa S; Montella E; Terracciano D; Morisco F; Portella G
Front Pharmacol; 2022; 13():891398. PubMed ID: 36059971
[No Abstract] [Full Text] [Related]
18. Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors.
Carrieri P; Carrat F; Di Beo V; Bourlière M; Barré T; De Ledinghen V; Pageaux GP; Bureau M; Cagnot C; Dorival C; Delarocque-Astagneau E; Marcellin F; Pol S; Fontaine H; Protopopescu C;
JHEP Rep; 2022 Jun; 4(6):100481. PubMed ID: 35514789
[TBL] [Abstract][Full Text] [Related]
19. Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents.
Yoo HW; Park JY; Kim SG; Jung YK; Lee SH; Kim MY; Jun DW; Jang JY; Lee JW; Kwon OS
Sci Rep; 2022 Jan; 12(1):193. PubMed ID: 34996920
[TBL] [Abstract][Full Text] [Related]
20. High Red Cell Distribution Width and Low Absolute Lymphocyte Count Associate With Subsequent Mortality in HCV Infection.
Damjanovska S; Davitkov P; Gopal S; Kostadinova L; Kowal C; Lange A; Moreland A; Shive CL; Wilson B; Bej T; Al-Kindi S; Falck-Ytter Y; Zidar DA; Anthony DD
Pathog Immun; 2021; 6(2):90-104. PubMed ID: 34988340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
